Image default
Synthetic Biology Technology

Researchers hope cell-free synthetic biology will help to aid the acceleration of Covid-19 therapeutics

“The idea is akin to opening the hood of a car and removing the engine, which allows researchers to use the engine for different purposes, free from the constraints of the car.”

Researchers have claimed that they have used cell-free synthetic biology to help them produce a drug that has proven effective in obliterating SARS-CoV in cellular cultures. The team hopes that the drug might also be effective in the fight against SARS’s close genetic cousin, the novel coronavirus (Covid-19).

The development has been led by Northwestern University (@NorthwesternU )and ShanghaiTech University (@ShanghaiTechUni).

In a statement, the team said it was able to produce its new drug by taking the molecular machinery out of cells, and then using that machinery to make a product, such as therapeutics, in a safe, inexpensive and rapid manner.

According to the researchers, it has produced a “promising” molecule called valinomycin in a cell-free system.

The idea is akin to opening the hood of a car and removing the engine, which allows researchers to use the engine for different purposes, free from the constraints of the car.

With this approach, they increased production yields more than 5,000 times in just a few rapid design cycles, achieving higher concentrations of the molecule than achieved previously in cells.

“Because we use cell-free systems, we can optimise production faster than in cells to further increase yields,” said Northwestern’s Michael Jewett, who co-led the study. “For example, pathway optimization cycles take days rather than weeks or months, and this speed could be ever so important when dealing with a pandemic like the coronavirus COVID-19 outbreak.”

The research was published online recently in the journal Metabolic Engineering and will appear in the July 2020 print issue.

Jewett is the Walter P. Murphy Professor of Chemical and Biological Engineering in the McCormick School of Engineering and director of Northwestern’s Center for Synthetic Biology. Jewett leads multiple projects that use cell-free biotechnology to accelerate COVID-19 therapeutics. car. He co-led the work with Jian Li, an assistant professor in the School of Physical Science and Technology at ShanghaiTech.

A naturally occurring peptide, valinomycin has recently emerged as a potential antiviral to treat SARS. Jewett imagines using cell-free synthetic biology to find similar molecules or to modify valinomycin to make it safer and more potent.

If you enjoyed reading this synthetic biology story, you may also enjoy reading the ones below.

Read: Japanese scientists find new metabolic engineering technique to improve biochemical production

Read: US Army synthetic biology project ‘may’ lead to new class of high-performance materials.

Read: Expert insights from day two of SynBio Markets 2019.

Read: Exclusive expert insights from day one of SynBio Markets 2019.

Speaker Interview: 5 Minutes With…Gernot Abel from Novozymes.

Speaker Interview: 5 Minutes With…Seiji Hirasaki from OriCiro Genomics.

Speaker Interview : 5 Minutes With…Kate Krueger from New Harvest.

Speaker Interview: 5 Minutes With…John Husnik from Renaissance BioScience.

Related posts

CO2 + sunlight = chemicals at Photanol’s planned new demo plant.

Luke Upton

New biocomposite made from 90 percent renewable feedstock delivers on strength and durability.

Emily Odowd

Conversion of loblolly pine into BTX progresses with Anellotech’s first successful performance test at pilot plant.

Luke Upton

Leave a Comment

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More